1 Flavivirology Laboratory, Department of Microbiology, 5 Science Drive 2, National University of Singapore, Singapore 117597, Singapore
2 School of Biological Sciences, Nanyang Technological University, 1, Nanyang Walk, Singapore 637616, Singapore
Correspondence
M.-L. Ng
micngml{at}nus.edu.sg
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Both J. J. H. Chu and R. Rajamanonmani contributed equally to this work.
![]() |
INTRODUCTION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
The WNV, like all flavivirus, is made up of three structural proteins, the large envelope protein (E), a single nucleocapsid protein (C) and a lipid membrane protein (M). Together with the C protein, the genome RNA forms an isometric nucleocapsid, while the M and E proteins, together with the host's membrane, form the envelope that surrounds the nucleocapsids (Murphy, 1980).
The flavivirus major envelope glycoprotein has a dual function: as a receptor binding protein, it is the primary determinant of host range, cell tropism, virulence and is a major antigen in eliciting neutralizing antibodies during the immune response (Roehrig, 2003). In addition, the envelope glycoprotein is responsible for fusing the virus and host membranes in the acidic milieu of the late endosomes (Chu & Ng, 2004
; Heinz & Allison, 2003
). The crystallographic structures of the tick-borne encephalitis (TBE) virus E protein and that of dengue-2 (Den 2) virus have been determined (Rey et al., 1995
; Modis et al., 2003
). Together with the E1 protein from alphaviruses, they have common structural and functional features which set them apart from the well-studied influenza haemaglutinin and have thus, been named class II fusion glycoproteins (Lescar et al., 2001
).
In their pre-fusion conformation, the glycoprotein E forms homodimers that lie flat on the outer surface of the virus particles (Rey et al., 1995; Kuhn et al., 2002
; Mukhopadhyay et al., 2003
). Each E protein monomer folds into three structural domains predominantly composed of
-strands. Domain I is centrally located in the structure and carries the N-glycosylation site. Structural domain II of the E protein promotes dimerization and bears the fusion loop that inserts into the target host membrane during the pH-dependent fusion of the virus (Modis et al., 2004
; Bressanelli et al., 2004
). Located at the C-terminal end of the molecule, domain III, which was named domain B in earlier antigenic mapping studies, carries several epitopes able to elicit virus-neutralizing antibodies (Roehrig, 2003
). In addition, studies with several flaviviruses including TBE (Mandl et al., 2001
) have also suggested that domain III, which has a fold typical of an immunoglobulin constant domain, could also mediate flavivirus attachment to host cells (Anderson, 2003
).
Since the C-terminal domain can fold independently into a stable conformation, it is therefore an attractive target to block infectivity either through the design of molecules that would compete with the whole virus to enter cells or by eliciting neutralizing antibodies. In addition, it should also be useful to help identify receptors and co-receptors located at the cell surface. In the present study, the putative receptor binding WNV-DIII was cloned, expressed, refolded and purified. The recombinant protein was subjected to circular dichroism (CD) spectroscopy to estimate its secondary structure, and the antigenic and antagonist properties were studied.
![]() |
METHODS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Cloning and expression of recombinant WNV-DIII protein.
The sequence corresponding to aa 299401 of the C-terminal domain III of the WNV(S) envelope protein was amplified by PCR using Advantage II polymerase enzyme (Clontech) and the following set of primers: forward primer, 5'-CAGCTCGAGGGAACAACATATGGTGTATGCTC-3' and reverse primer, 5'-ACCGGATCCTTACCCAGATTTGTGCCAGTG G-3'. The XhoI and BamHI restriction sites are underlined. The PCR product of 440 bp was digested with the restriction enzymes XhoI and BamHI and ligated into the BamHI/XhoI sites of the pET16b vector (Novagen). The nucleotide sequence was confirmed by using DNA sequence analysis. E. coli cells [strain BL21(DE3)] with the pET16b vector containing the inserted fragment were grown until OD600 of the culture reached 0·6, and protein expression was induced by adding IPTG to a final concentration of 0·5 mM at 30 °C for 46 h. Cells were harvested by centrifugation at 5000 g for 20 min at 4 °C and washed twice with a buffer containing 1 % NP40, 20 µg ml1 DNase and 1 mM PMSF. Cell lysis was performed in a French pressure cell at 1200 p.s.i. (8280 kPa), followed by centrifugation at 48 000 g for 30 min at 4 °C (Beckman). The recombinant protein was expressed in the insoluble fraction as inclusion bodies as shown by SDS-PAGE.
Purification of recombinant WNV-DIII protein.
Inclusion bodies were solubilized in 8 M urea and passed through a Ni-NTA agarose column (Qiagen) for affinity purification. The protein was eluted at pH 2·4. The pH was then adjusted to 7·9 and the protein diluted to a concentration of 510 µg ml1. Refolding was carried out through extensive dialysis at 4 °C against a buffer containing 50 mM Tris/HCl, 1 mM EDTA, 20 % glycerol, 100 mM NaCl and 3 mM DTT at pH 8·0. After concentration by ultrafiltration using a molecular mass cut-off of 5 kDa (Amicon), the protein was purified by size exclusion chromatography (Superdex 75; Amersham) in a buffer containing 12 mM Tris/HCl, 200 mM NaCl and 5 mM DTT at pH 8·0. Western blot analysis was performed using an anti-penta-histidine antibody (Qiagen). In order to confirm the identity of the protein cleavage of the His tag was carried out using Factor Xa (Qiagen) following the manufacturer's recommendations, and sequencing of the first 10 aa from the cleaved product were obtained using Edman degradation on an Applied Biosystems sequencer.
Analysis by CD.
The CD spectra were recorded on a Jasco J810 spectro-polarimeter by using three accumulations of data at 0·1 nm intervals and were smoothed using the noise reduction routines provided with the instrument, including solvent background subtraction. The buffer used was 12 mM Tris/HCl, 10 mM sodium phosphate, 2 mM DTT at pH 8·0 and the protein concentration was 0·1 mg ml1. Deconvolution of the CD far UV-spectrum was carried out with the CDNN and CONTIN software (Sreerama & Woody, 2000). Mass spectrometry analysis using a matrix-assisted laser desorption ionization time of flight mass spectrometer (MALDI-TOF) was used to determine the molecular mass of the sample.
Generation of murine polyclonal antibodies against soluble WNV-DIII protein.
Soluble WNV-DIII protein was incubated with ImmunEasy mouse adjuvant (Qiagen) at a concentration recommended by the manufacturer. The antigenadjuvant mixture was used to immunize BALB/c mice five times subcutaneously at 14-day intervals. Mouse sera were collected 12 days after the last booster. Mouse sera were purified using Econo-Pac serum IgG purification kits (Bio-Rad) and dialysed overnight with PBS. The purified immunoglobulins were stored at 20 °C. Sera were tested by Western blot detection for the presence and specificity of antibodies against the WNV-DIII protein as described previously in Chu & Ng (2002).
Inhibition of WNV infection by soluble WNV-DIII protein.
Soluble WNV-DIII protein or BSA (in the concentration range of 5100 µg ml1) was incubated with either Vero or C6/36 cells (1x106 cells) in cell culture medium at 4 °C for 1 h. Unbound protein molecules were removed by washing the cells three times with PBS. This was followed by incubating with 1x104 p.f.u. ml1 of 35S-methionine labelled WNV or Den 2 virus for 1 h at 37 °C. The ratio of WNV-DIII molecules to WNV/Den 2 virus particles is 5 : 1. After the incubation period, excess or unbound virus were inactivated with acid citrate buffer, pH 2·8 (Chu & Ng, 2003) and removed by washing three times with PBS. The cells were then lysed with 1 % SDS and the specific radioactivity was determined. Three independent experiments were carried out.
Plaque neutralization assay.
Purified murine polyclonal antibodies generated against soluble WNV-DIII protein or pre-immune sera (control) were evaluated using plaque reduction assay to determine the neutralization ability of these antibodies on WNV or Den 2 virus infectivity. Fifty microlitres of antibodies (500 µg ml1) in twofold serial dilutions (from 1 : 2 to 1 : 8192) were prepared in microcentrifuge tubes. The WNV or Den 2 virus was adjusted to 500 p.f.u. in 50 µl of virus diluent (10 % concentrated Hanks' balanced salt solution, 0·1 % BSA; pH 7·27·4) was added to the tube containing serial diluted antibodies. The antibody and virus was mixed, pulse centrifuged and then incubated at 37 °C for 1 h. A 24-well plate with confluent monolayer of Vero cells was used for virus infection. Before inoculation of the antibodyvirus mixture, the cell monolayer was rinsed once with virus diluent, after which 100 µl of the antibodyvirus mixture was added to the appropriate wells. The plates were left at 37 °C for 1 h, and rocked at 15 min intervals. After incubation, the inocula were removed and the cell monolayer was rinsed once with virus diluent. Overlay medium (2 % carboxymethly cellulose in M199 containing 2 % FCS) was added and incubated further at 37 °C for 4 days, and virus plaques were stained with 0·5 % crystal violet. Three independent experiments were carried out.
![]() |
RESULTS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
|
The amino acid sequences of the recombinant WNV-DIII protein [WNV(S) and WNV (NY)] were aligned with the sequences of other flaviviruses namely: Yellow fever virus [(vaccine strain 17D) (17D YF)], TBE virus, Den 2 virus, Japanese encephalitis virus (JE), Kunjin (Kun) virus, Murray Valley encephalitis (MVE) virus and Langat virus (Lgt) (Fig. 2). Secondary structure elements (
-strands 17) are represented above the sequences as reported by Rey et al. (1995)
. The single conserved disulphide bond is indicated by a dotted line. The RGD/RGE integrin-binding motif present in YF, JE and MVE viruses is located in the loop between
6 and
7 strands of DIII. The known antigenic regions 307, 330332 and 390 are indicated in bold characters.
|
|
|
To rule out the presence of other bacterial proteins that may co-purify with WNV-DIII protein and participate in blocking virus attachment, supernatant of bacterial cell lysate not expressing WNV-DIII (purified in the same manner as for recombinant WNV-DIII protein) was used to assess virus binding. The E. coli cell lysate inhibited WNV and Den 2 virus binding to Vero and C6/36 cells at a low level of not more than 2 %. This was less than that observed using BSA as a competitor (approx. 5 %) (data not shown). Therefore, these results confirm that WNV-DIII protein is responsible for binding to the cell surface of both vertebrate and invertebrate cells and the plausibility of WNV and Den 2 virus sharing the same attachment/receptor molecule(s) in C6/36 cells.
Murine polyclonal antibodies to recombinant WNV-DIII protein neutralized WNV
To affirm further that WNV-DIII protein is indeed the receptor-binding domain, murine polyclonal antibodies against recombinant WNV-DIII were produced and used for plaque neutralization assay of WNV. The murine polyclonal was specific in detecting WNV-DIII protein in a Western blot (data not shown). Plaque neutralization assays were then carried out for both WNV and Den 2 virus with a dilution series of antibodies against WNV-DIII protein. At dilution of 1 : 64, there was at least 90 % neutralization of the WNV (Fig. 5a). High neutralization (80 %) of the WNV was maintained until the murine polyclonal antibodies were diluted to 1 : 256. At higher dilutions, there was an exponential decrease in the degree of neutralization reaching 0 % when the dilution factor was 1 : 8192. When the WNV was reacted with the pre-immunized sera, no neutralization effect was observed. In contrast, Den 2 virus was only partially inhibited (50 %) at low dilution (<1 : 64) of the antibodies and minimal neutralization effect was observed with higher dilution of the antibodies (>1 : 256) (Fig. 5b
).
|
![]() |
DISCUSSION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
In the protocol used in this study, the truncated protein was obtained within inclusion bodies and a refolding procedure was performed. Despite the relative high yield and ease of purification, the procedure introduced an uncertainty about the exact proportion of protein molecules, which have the native fold. Indeed, some proteins associated as dimers or trimers via the formation of non-native inter-monomer disulfide bonds. Most of these misfolded proteins were eliminated during the size-exclusion chromatography step. Proper folding of the expressed recombinant WNV-DIII protein is of paramount importance since it has been shown that a reduced and denatured WNV E glycoprotein was unable to elicit neutralizing antibodies in mice (Wengler & Wengler, 1989). The secondary structure composition of the recombinant WNV-DIII protein derived from CD indicates an anti-parallel
-strands conformation consistent with the experimentally determined structures of other flaviviruses envelope protein ectodomains (Rey et al., 1995
; Modis et al., 2003
) or DIII fragments (Wu et al., 2003
; Volk et al., 2004
).
The sites of mutations that affect host range or virulence has been mapped on the major flavivirus envelope protein (Rey et al., 1995). They cluster at the hinge junction between domain I and III next to the fusion loop, which is buried in the dimer interface and in domain III. In the virus structure (Kuhn et al., 2002
; Mukhopadhyay et al., 2003
) the lateral face of domain III is largely exposed. In particular, residues located around positions 305308, 330333 and 384386 are clustered on the upper surface of WNV-DIII, which is exposed to the solvent and hence accessible to antibodies. Residue 307 is a lysine in WNV-DIII protein and also in TBE virus but is acidic in other flaviviruses (JE virus and MVE virus). Position 307 is a hot spot for mutation enabling the generation of flavivirus escape mutants (Beasley & Barrett, 2002
; Chambers et al., 1998
). Residues Ser331 and Asp332 [corresponding respectively to Lys332 and Asp333 in WNV(S)] belong to a neutralizing epitope on JE virus (Lin & Wu, 2003
). Thus, a number of these residues which belong to virus-neutralizing epitopes (Beasley & Barrett, 2002
; Lin & Wu, 2003
; Wu et al., 2003
; Volk et al., 2004
) account for the antigenic fine structure of the flavivirus E protein, and are likely to be involved in determining the binding specificity for different cell types (Hung et al., 2004
). In this study, a polyclonal anti-WNV-DIII protein serum was produced in mice. The serum was able to neutralize WNV (Fig. 5a
). This suggested that the conformational epitopes on the purified refolded protein were correctly presented at the external surface and the WNV-DIII recombinant protein adopts a native fold.
At the surface of the virion, DIII cluster around fivefold icosahedral axis (Kuhn et al., 2002; Mukhopadhyay et al., 2003
) and such pentameric clusters might be a more efficient way to elicit neutralizing antibodies that would possibly interfere with receptor binding. It is interesting to note that the Langat virus DIII protein crystallizes with five monomers per asymmetric unit thus possibly mimicking the arrangement found on the viral surface (White et al., 2003
).
Domain III was initially postulated to form the receptor-binding site for the virus particles because of its exposed location at the surface of the virus (Rey et al., 1995; Kuhn et al., 2002
; Mukhopadhyay et al., 2003
). In addition, the presence of a tripeptide Arg-Gly-Asp motif in the loop connecting strands
6 and
7 of several mosquito-borne flaviviruses E protein (e.g. MVE virus and several strains of JE virus) (Fig. 2
) suggested that this motif could bind to the integrin family of cell-surface matrix receptors. This hypothesis, however, was not supported by mutagenesis studies of the YF virus (Van der Most et al., 1999
) and cellular receptors are still not unequivocally identified for flaviviruses. Indeed a range of different surface molecules could act as flavivirus receptors on different cell types (Anderson, 2003
). The fact that the recombinant WNV-DIII protein was able to substantially inhibit infection with the Den 2 virus in C6/36 cells (Fig. 4b
) indicated that the attachment/receptor molecules situated at the surface of the mosquito cells may be common for both WNV and Den 2 virus. Work is in progress to address this interesting issue.
However, the lack of high antagonistic effect of WNV-DIII on Den 2 virus infection (Fig. 4a) in Vero cells as compared to WNV, may suggest that the two viruses utilized a different set of attachment or receptor molecules for binding to Vero cells. This was consistent with the observation that the murine polyclonal antibodies against WNV-DIII also failed to exhibit high neutralization effect on Den 2 virus (Fig. 5b
).
Glycosaminoglycans such as heparan sulfate and choindritin sulfate (negatively charged carbohydrates) present on the surface of many vertebrate cells were proposed to be involved in the attachment and entry of Den 2 virus (Chen et al., 1997). However, treatment with heparinase on vertebrate cells (Chu & Ng, 2003
) did not significantly inhibit infection with WNV. Instead, a 105 kDa protease-sensitive, N-linked glycoprotein has been implicated to mediate attachment and entry of WNV into permissive vertebrate cells (Chu & Ng, 2003
). Other studies also suggested that heparan sulfate may not necessary serve as the universal flavivirus attachment or receptor molecule on cell surfaces (Bielefeldt-Ohmann et al., 2001
; Kroschewski et al., 2003
).
The entry process of WNV into both vertebrate and invertebrate is poorly understood and this process is important in explaining tissue tropism and pathogenesis of WNV infection. To our knowledge, this study has defined direct evidence, for the first time, that DIII of the WNV envelope protein is involved in binding to cell surface molecules for both Vero and C6/36 cells. However, we cannot exclude any possibility that other domains of the envelope protein may also be necessary for post-binding process of WNV entry into host cells. Future work is also necessary to elucidate the molecular mechanism of WNV entry mechanism. Nevertheless, the identification of the receptor-binding domain of WNV envelope protein can serve as a potential target for the design of anti-viral agent development to eradicate this emerging flavivirus infection.
![]() |
ACKNOWLEDGEMENTS |
---|
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Beasley, D. W. C. & Barrett, A. D. T. (2002). Identification of neutralizing epitopes within structural domain III of the West Nile virus envelope protein. J Virol 76, 1309713100.
Bhardwaj, S., Holbrook, M., Shope, R. E., Barrett, A. D. T. & Watowich, S. J. (2001). Biophysical characterization and vector-specific antagonist activity of domain III of the tick-borne flavivirus envelope protein. J Virol 75, 40024007.
Bielefeldt-Ohmann, H., Meyer, M., Fitzpatrick, D. R. & Mackenzie, J. S. (2001). Dengue virus binding to human leukocyte cell lines: receptor usage differs between cell types and virus strains. Virus Res 73, 8189.[CrossRef][Medline]
Boctor, F. N., Calisher, C. H. & Peter, J. B. (1989). Dot-ELISA for serodiagnosis of human infections due to Western equine encephalitis virus. J Virol Methods 26, 305311.[CrossRef][Medline]
Bressanelli, S., Stiasny, K., Allison, S. L., Stura, E. A., Duquerroy, S., Lescar, J., Heinz, F. X. & Rey, F. A. (2004). Structure of a flavivirus envelope glycoprotein in its low-pH-induced membrane fusion conformation. EMBO J 23, 728738.
CDC (1999). Update: West Nile virus encephalitis New York 1999. MMWR Morbid Mortal Wkly Rep 48, 944946.
CDC (2002). Update: West Nile virus encephalitis New York 1999. MMWR Morbid Mortal Wkly Rep 51, 11351136.[Medline]
Chambers, T. J., Halevy, M., Nestorowicz, A., Rice, C. M. & Lustig, S. (1998). West Nile virus envelope proteins: nucleotide sequence analysis of strains differing in mouse neuroinvasiveness. J Gen Virol 79, 23752380.[Abstract]
Chen, Y., Maguire, T., Hileman, R. E., Fromm, J. R., Esko, J. D., Linhardt, R. J. & Marks, R. M. (1997). Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate. Nat Med 3, 866871.[Medline]
Chu, J. J. H. & Ng, M. L. (2002). Trafficking mechanism of West Nile (Sarafend) virus structural proteins. J Med Virol 67, 127136.[CrossRef][Medline]
Chu, J. J. H. & Ng, M. L. (2003). Characterization of a 105-kDa plasma membrane associated glycoprotein that is involved in West Nile virus binding and infection. Virology 312, 458469.[CrossRef][Medline]
Chu, J. J. H. & Ng, M. L. (2004). Infectious entry of West Nile virus occurs through a clathrin-mediated endocytic pathway. J Virol 78, 1054310555.
George, S., Gourine-Devi, M., Rao, J. A., Prasad, S. R. & Pavri, K. M. (1984). Isolation of West Nile virus from the brain of children who had died of encephalitis. Bull W H O 62, 879882.[Medline]
Heinz, F. X. & Allison, S. L. (2003). Flavivirus structure and membrane fusion. Adv Virus Res 59, 6397.[CrossRef][Medline]
Hung, J. J., Hsieh, M. T., Young, M. J., Kao, C. L., King, C. C. & Chang, W. (2004). An external loop region of domain III of dengue virus type 2 envelope protein is involved in serotype-specific binding to mosquito but not mammalian cells. J Virol 78, 378388.
Kroschewski, H., Allison, S. L., Heinz, F. X. & Mandl, C. W. (2003). Role of heparan sulfate for attachment and entry of tick-borne encephalitis virus. Virology 308, 92100.[CrossRef][Medline]
Kuhn, R. J., Zhang, W., Rossmann, M. G. & 9 other authors (2002). Structure of dengue virus: implications for flavivirus organization, maturation, and fusion. Cell 108, 717725.[Medline]
Lescar, J., Roussel, A., Wien, M. W., Navaza, J., Fuller, S. D., Wengler, G., Wengler, G. & Rey, F. A. (2001). The fusion glycoprotein shell of Semliki Forest virus: an icosahedral assembly primed for fusogenic activation at endosomal pH. Cell 105, 137148.[Medline]
Lin, C. W. & Wu, S.-C. (2003). A functional epitope determinant on domain III of the Japanese encepahalitis envelope protein interacted with neutralizing-antibody combining sites. J Virol 77, 26002606.
Mandl, C. W., Kroschewski, H., Allison, S. L., Kofler, R., Holzmann, H., Meixner, T. & Heinz, F. X. (2001). Adaptation of tick-borne encephalitis virus to BHK-21 cells results in the formation of multiple heparan sulfate binding sites in the envelope protein and attenuation in vivo. J Virol 75, 56275637.
Modis, Y., Ogata, S., Clements, D. & Harrison, S. C. (2003). A ligand-binding pocket in the dengue virus envelope glycoprotein. Proc Natl Acad Sci U S A 100, 69866991.
Modis, Y., Ogata, S., Clements, D. & Harrison, S. C. (2004). Structure of the dengue virus envelope protein after membrane fusion. Nature 427, 313319.[CrossRef][Medline]
Mukhopadhyay, S., Kim, B. S., Chipman, P. R., Rossmann, M. G. & Kuhn, R. J. (2003). Structure of West-Nile virus. Science 302, 248.
Murphy, F. A. (1980). Togavirus morphology and morphogenesis. In The Togavirus. Biology, Structure, Replication, pp. 241316. Edited by R. W. Schlesinger. New York: Academic Press.
Rey, F. A., Heinz, F. X., Mandl, C., Kunz, C. & Harrison, S. C. (1995). The envelope glycoprotein from tick-borne encephalitis virus at 2 Å resolution. Nature 375, 291298.[CrossRef][Medline]
Roehrig, J. T. (2003). Antigenic structure of flavivirus proteins. Adv Virus Res 59, 141175.[CrossRef][Medline]
Roehrig, J. T., Bolin, R. A. & Kelly, R. G. (1998). Monoclonal antibody mapping of the envelope glycoprotein of the dengue 2 virus, Jamaica. Virology 246, 317328.[CrossRef][Medline]
Smithburn, K. C., Taylor, R. M., Rizk, F. & Kader, A. (1954). Immunity to certain arthropod-borne viruses among indigenous residents of Egypt. Am J Trop Med Hyg 3, 918.[Medline]
Sreerama, N. & Woody, R. W. (2000). Estimation of protein secondary structure from circular dichroism spectra: comparison of CONTIN, SELCON, and CDSSTR methods with an expanded reference set. Anal Biochem 287, 252260.[CrossRef][Medline]
Tetin, S. Y., Prendergast, F. G. & Venyaminov, S. Y. (2003). Accuracy of protein secondary structure determination from circular dichroism spectra based on immunoglobulin examples. Anal Biochem 321, 183187.[CrossRef][Medline]
van der Most, R. G., Corver, J. & Strauss, J. H. (1999). Mutagenesis of the RGD motif in the yellow fever virus 17D envelope protein. Virology 265, 8395.[CrossRef][Medline]
Volk, D. E., Beasley, D. W. C., Kallick, D. A., Holbrook, M. R., Barrett, A. D. T. & Gorenstein, D. G. (2004). Solution structure and antibody binding studies of the envelope protein domain III from the New York strain of West Nile virus. J Biol Chem 279, 3875538761.
Wengler, G. & Wengler, G. (1989). Cell-associated West Nile flavivirus is covered with E+pre-M protein heterodimers which are destroyed and reorganized by proteolytic cleavage during virus release. J Virol 63, 25212526.[Medline]
White, M. A., Liu, D., Holbrook, M. R., Shope, R. E., Barrett, A. D. T. & Fox, R. O. (2003). Crystallization and preliminary X-ray diffraction analysis of Langat virus envelope protein domain III. Acta Crystallogr D Biol Crystallogr 59, 10491051.[CrossRef][Medline]
Wu, K. P., Wu, C. W., Tsao, Y. P., Kuo, T. W., Lou, Y. C., Lin, C. W., Wu, S. C. & Cheng, J. W. (2003). Structural basis of a flavivirus recognized by its neutralizing antibody: solution structure of the domain III of the Japanese encephalitis virus envelope protein. J Biol Chem 278, 4600746013.
Received 1 July 2004;
accepted 6 October 2004.